Third Quarter
March 2016
Webcast and Conference Call

May 10, 2016

Participant Dial In Numbers

U.S. Toll-Free	*+1-877-853-5634*
International Toll	*+1-315-625-6893*
Conference ID	*52883099*

Cautionary Statement

Forward-Looking Statements

This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, -future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “believe,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.

Non-GAAP Financial Information

We use non-GAAP financial measures, such as adjusted EBITDA, adjusted net income and pro forma adjusted diluted earnings per share, to assess and analyze our operational results and trends and to make financial and operational decisions. Management uses adjusted EBITDA as its primary operating measure. We report Adjusted Net Income to portray the results of our operations prior to considering certain income statement elements. We report pro forma adjusted diluted earnings per share to reflect the pro forma effects of the IPO and refinancing on all periods presented. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this communication should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this communication and/or our Quarterly Report on Form 10-Q.

Internet Posting of Information

We routinely post information that may be important to investors in the “Investors” section of our website at www.pahc.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Participants

Jack Bendheim

Chairman, President, Chief Executive Officer

Richard Johnson

Chief Financial Officer

MFAs Update

- Continued international volume growth of MFAs, with revenues tempered by pricing pressures from the strong U.S. dollar
- Some U.S. producers are reducing antibacterial usage
  - In advance of FDA regulatory changes to remove growth promotion claims for medically important antibacterials, effective January 2017
  - Growing consumer preferences to reduce/eliminate antibacterials in protein production
  - Balanced with the ongoing need for therapeutic treatment of diseases
    - Animal welfare
    - Food safety
    - Affordable food
- Phibro's current annual U.S. sales of medically important antibacterials for use in animal health are approximately $40 million
  - Some portion of these sales are at risk due to the factors discussed above

MFAs Update (continued)

- FDA initiated steps to withdraw approval of the swine drug carbadox
  - Safety is our highest priority and we have complete confidence in the product.
  - We intend to continue to collaborate fully with the FDA to provide and evaluate scientific data which we expect will address the FDA's concerns.
  - We have requested a hearing with the FDA to address its concerns
    - In accordance with the FDA process
  - Timeline for FDA's decision is undefined.
  - FDA's action does not prohibit sale or use of the product. We continue to sell the product.
  - Phibro's current annual U.S. sales of carbadox are approximately $15 million.

Q3 Results – March 2016

- Consolidated sales (1)%
  - Animal Health volume growth
  - Mineral Nutrition volume growth offset by lower commodity pricing
- Gross profit +8%, ex-acquisition related
  - Volumes and mix
  - Improved operating efficiencies
  - Favorable cost of goods from volumes and currencies
- SG&A +2%, ex-acquisition related
  - Animal Health selling, marketing, development
- Adjusted EBITDA +16%
- Adjusted diluted EPS +6%
  - Growth in adjusted EBITDA
  - Cash income taxes increased due to mix of international pre-tax income

Consolidated

For the three months ended March 31	2016	2015 ex-licensing	Change ex-licensing	
	(in millions, except per share)			
Animal Health	$ 118.3	$ 115.3	3.0	*3%*
Mineral Nutrition	53.0	57.3	(4.3)	*(7)%*
Performance Products	12.1	12.8	(0.7)	*(6)%*
Net sales	$ 183.5	$ 185.5	(2.0)	*(1)%*
Gross profit	60.0	57.1	2.8	*5%*
% of net sales	*32.7%*	*30.8%*		
SG&A	38.8	37.3	1.5	*4%*
% of net sales	*21.1%*	*20.1%*		
Adjusted EBITDA	$ 29.7	$ 25.5	4.2	*16%*
% of net sales	*16.2%*	*13.7%*		*+250bps*
Adjusted diluted EPS	$ 0.38	$ 0.36	0.02	*6%*

Comparisons exclude $2.0 million of 2015 milestone payments for licensing of vaccine delivery technology. Adjustments exclude acquisition-related cost of goods sold, acquisition-related intangible amortization expense, acquisition-related accrued compensation, acquisition-related transaction costs, foreign currency gains or losses and acquisition-related accrued interest. Adjusted diluted EPS reflects cash income taxes paid.

Animal Health

- Sales +3%
  - Volume growth
  - MFAs and other: international growth offset by domestic reductions
  - Nutritional specialties: dairy focus; poultry product introduction in U.S.
  - Vaccines: MVP acquisition offset by international production upgrades
- Adjusted EBITDA +16%
  - EBITDA margin +320bps
  - Gross profit growth: volumes, product mix and favorable manufacturing costs
  - Modest operating expense investments

Animal Health

For the three months ended March 31	2016	2015 ex-licensing	Change ex-licensing	
		(in millions)		
MFAs and other	$ 82.4	$ 83.4	$ (0.9)	*(1)%*
Nutritional specialties	22.8	19.8	3.0	*15%*
Vaccines	13.1	12.1	0.9	*8%*
Net sales	$118.3	$ 115.3	**$ 3.0**	***3%***
Adjusted EBITDA	$ 32.2	$ 27.6	$ 4.5	*16%*
% of segment net sales	*27.2%*	*24.0%*		*+320bps*

Other Segments

- Mineral Nutrition
  - Volume growth offset by lower commodity pricing
  - Operating margin up on sales mix
- Performance Products
  - Operating margin decline on sales mix
- Corporate

For the three months ended March 31	2016	2015	Change	
		(in millions)		
Mineral Nutrition				
Net sales	$53.0	$ 57.3	$ (4.3)	*(7)%*
Adjusted EBITDA	$ 4.0	$ 3.8	$ 0.3	*7%*
% of segment net sales	*7.6%*	*6.6%*		*+100bps*
Performance Products				
Net sales	$12.1	$ 12.8	$ (0.7)	*(6)%*
Adjusted EBITDA	$ 0.5	$ 1.0	$ (0.5)	*(51)%*
% of segment net sales	*4.0%*	*7.7%*		*-370bps*
Corporate				
Adjusted EBITDA	$ (7.0)	$ (6.9)	$ (0.1)	*

** Calculation not meaningful*

Capitalization and Capital Allocation
March 31, 2016

- 3.3x leverage ratio at March 31, 2016
  - $367 million total debt
  - $113 million LTM adjusted EBITDA
- $32 million cash on hand at March 31, 2016
- Net cash flow before financing was a $53 million use of cash in the March 2016 quarter
  - MVP acquisition used $47 million
  - Working capital and other items used $15 million of cash
  - Capex of $11 million
- Quarterly dividend of $0.10 per common share
  - $3.9 million paid March 2016
  - $3.9 million to be paid June 2016

Updated Guidance

Phibro ANIMAL HEALTH CORPORATION ™

Consolidated

For the years ended June 30

(in millions, except per share)	2016 Updated Guidance	2015 ex-licensing	Growth [1]	2015 reported	Growth
Net sales	$ 745 - $ 750	$ 741	*approximately 1%*	$ 749	*(1)% - 0%*
Adjusted EBITDA	$ 114 - $ 115	$ 102	*12% - 13%*	$ 110	*4% - 5%*
ratio	*15.3% 15.3%*	*13.8%*	*+150bps*	*14.7%*	*+060bps*
Adjusted EPS	$ 1.58 - $ 1.60	$ 1.52	*4% - 5%*	$ 1.72	*(8)% - (7)%*

[1] *Excludes $8 million of vaccine licensing milestone revenues and income included in the 2015 reported results*

- Our Animal Health revenues for fiscal year 2016 are expected to be approximately $477-$482 million, representing growth of approximately 3% - 4% and accounting for more than all the consolidated sales growth. Within the Animal Health segment, we expect nutritional specialties and vaccines will continue to grow at double-digit rates; we expect MFAs and other will be even with or slightly above the prior year. Mineral Nutrition revenues are expected to decline approximately 4% from last year as volume increases are offset by lower commodity pricing. Performance Products revenues are expected to decline modestly from the prior year.

- We expect our operating margin to expand to approximately 15.3% for the year, a 150 bps improvement over fiscal year 2015, excluding the vaccine licensing milestone revenue and income. We expect an improved gross profit ratio, due to a combination of favorable business and product mix and favorable currency benefits on manufacturing costs, will be the principal contributor to the expanded operating margin.

- We expect interest expense, net of $15 million, an increase over the initial guidance due to financing costs for the MVP acquisition and for higher than expected working capital requirements.

- We expect cash income taxes of approximately $18 million for fiscal year 2016, equivalent to approximately 22% of adjusted income before income taxes. Cash income taxes are expected to increase due to the mix of international pre-tax income.

QUESTIONS AND ANSWERS